Navigation Links
Intrexon Establishes "Living Arts" Company, BioPop, to Create Consumer Products Inspired by Nature and Made Possible through Science
Date:10/2/2013

GERMANTOWN, Md. and CARLSBAD, Calif., Oct. 2, 2013 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today the formation of a new "Living Arts" subsidiary called Biological & Popular Culture, Inc. (BioPop).

BioPop's team of innovative scientists and creative designers, enabled by the synthetic biology engineering technology of Intrexon, aims to create new bio-diverse products like those found in nature. The company plans to utilize the promise of synthetic biology in the field of fine and decorative arts, accessories, toys and unique novelties.  The embedded concept is "living art."

To accelerate development of new concepts Intrexon acquired a controlling equity stake in Yonder Biology, now renamed BioPop, although its principals remain significant equity owners.  Yonder's co-founder, Andy Bass, has been named BioPop's Chief Executive Officer.

"BioPop will use living organisms as bio-palettes that live, grow and respond to stimuli," Bass said.  "Imagine an art piece that 'paints' itself; a living, renewable ambient light source that operates on sunlight, water and nutrients, instead of batteries or electricity. We'll use the same technology to create toys that inspire children through novel uses of nature – combining innovation, entertainment and imagination."

"BioPop aims to evolve the traditional biotechnology industry paradigm that focuses on healthcare and therapeutics.  We are transforming biotechnology to exist in people's everyday lives.  The consumer market is large with diverse interests that will play a vibrant role in biotech's future," Bass concluded.

Andy and his team were the creators of Dino Pet, the world's first living, bioluminescent pet made from
'/>"/>

SOURCE Intrexon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intrexon and Rentokil Enter into Research and Development Agreement to Explore a New Generation of Highly-Effective, Sustainable Pest Controls
2. Intrexon Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option by Underwriters
3. Intrexon Prices Initial Public Offering
4. Intrexon Announces Filing of Registration Statement For Proposed Initial Public Offering
5. Intrexon Organizes Around New Synthetic Biology Markets
6. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
7. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
8. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
9. ThromboGenics Establishes Level 1 ADR Program for US Investors
10. Pittcon Establishes a Collaborative Program Resource Team for 2014
11. Alacrita Establishes U.S. Headquarters in Boston Area
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The ... (Medication Dispensing Systems, Packaging and Labeling Systems, Table-top ... Automation) - Global Forecasts & Trends to 2019” ... and opportunities in North America, Europe, Asia-Pacific, and ... 101 market tables and 30 figures spread through ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
(Date:10/20/2014)... GAITHERSBURG, Md. , Oct. 20, 2014  GenVec, Inc. ... Zola P. Horovitz , Ph.D., from its board of ... GenVec board in August 2003, and served as its chairman ... also served on the Nominating and Corporate Governance and Audit ... Zola for more than a decade of dedicated service to ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2
... on nanoimprinting techniques (NIL) is evolving at a rapid pace. ... in order to reach the market? How do we bridge ... industry? What are the tools needed for each product? ... to life science products were discussed by more than 80 ...
... Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today ... of 2012. First Quarter Financial ResultsFor ... $18.1 million compared to $20.1 million for the same period ... to $17.4 million ($0.09 per share) for the quarter ended ...
... Fla., April 19, 2012  New data presented today ... delivering inhaled nitric oxide (NO) to patients being ... ), a privately held, advanced development-stage technology company, ... System during Right Heart Catheterization (RHC) in subjects ...
Cached Biology Technology:Tackling the European market of nanoimprint lithography 2Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 2Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 3Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 4Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 5New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 2New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 3New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 4
(Date:10/19/2014)... access in India over the last 30 years ... emissions growth during that time, according to a ... Climate Change ., "Energy access is fundamental to ... life, including education, communication, and health," says IIASA ... While increased energy access is widely agreed to ...
(Date:10/17/2014)... Rockville, MD – Accurate knowledge regarding Ebola is critical ... current risk of hazardous global outbreak and epidemic. The ... has launched a special issue, Ebola Virus and Public ... with necessary knowledge in this critical societal moment. ... Primer on Ebola for Clinicians . The primer was ...
(Date:10/16/2014)... body. Battles are won, lost or sometimes end ... as tumor dormancy—can last up to 25 years ... poorly understood. , A new computational model ... Professor of Chemistry at Princeton University, may help ... switch to a malignant state. Published today in ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Modeling tumor dormancy 2
... 2010 Imagine creating novel devices with amazing and ... a droplet of particles on a surface. By ... team of Harvard researchers, in collaboration with scientists at ... the University of Houston, has developed just that. ...
... Ardipithecus ramidus a purported human ancestor ... is coming under fire from scientists who say there ... dense woodlands at the African site where the creature lived ... for open savanna habitats," says University of Utah geochemist Thure ...
... State University College of Medicine researcher has discovered a new ... that may be the cause of B-cell lymphoma. The finding ... of other types of cancer, leading to further understanding of ... Yoichi Kato, an assistant professor in the Department ...
Cached Biology News:Applied physicists create building blocks for a new class of optical circuits 2Applied physicists create building blocks for a new class of optical circuits 3Out of the woods for 'Ardi' 2Out of the woods for 'Ardi' 3Out of the woods for 'Ardi' 4Medical researcher's discovery may explain how certain cancers develop 2
... 97 Cytological Labeling Kit provides a unique ... of cellular targets, including cell-surface receptors and ... Kit contains the patented ELF 97 phosphatase ... precipitate at the site of enzymatic activity ...
... between the various commercial and lab-prepared glass ... the length and GC content of the ... protocol employed all influence the optimal hybridization ... all the different variables to consider, it ...
... Stain combo offers these benefits: ... Offers a safer and ... Eliminates risks to yourself, the environment and your ... bp to >30 kb. UltraPure Agarose is a standard ...
This is a PYREX replacement Allihn condenser with a 34/45 inner joint on the bottom for the No. CLS3840-S 125mL extractor system. The tubulation O.D. on the condenser is 10mm....
Biology Products: